It’s Your Heart. Protect It. The Podcast. It’s Your Heart. Protect It. The Podcast. In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Zongertinib positive results non-small cell lung cancer Zongertinib positive results non-small cell lung cancer Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
new_analysis_nintedanib_SSc_ILD new_analysis_nintedanib_SSc_ILD Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
IPF why wait? IPF why wait? IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Spanish-Gazpacho Video Spanish-Gazpacho Video Find out how this light and delicious Spanish Gazpacho from Taking Cancer on Through Flavour is made.
Banana Coconut Bread Banana Coconut Bread Find out how to make this sweet, mouth-watering banana coconut bread recipe from Taking Cancer on Through Flavour and Taste Life.
FDA approval NexGard PLUS for dogs FDA approval NexGard PLUS for dogs Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Boehringer Ingelheim good 2021 business performance Boehringer Ingelheim good 2021 business performance 2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Research Beyond Borders Partnering Research Beyond Borders Partnering Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
sustainably fighting rabies info hub sustainably fighting rabies info hub Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
InSensitive Content: impact on the GPP patient community InSensitive Content: impact on the GPP patient community Understand why the patient community should be able to post and consume visual content related to generalized pustular psoriasis.
Welcome to Innovation at Boehringer Ingelheim Welcome to Innovation at Boehringer Ingelheim Watch our video and find out more about innovation at Boehringer Ingelheim.
The Unwearable Collection - The GPP patient experience The Unwearable Collection - The GPP patient experience The Unwearable Collection™ is a fashion line based on the experiences of patients living with generalized pustular psoriasis, designed by Bart Hess.
Collaboration with Mary Tyler Moore Vision Initiative Collaboration with Mary Tyler Moore Vision Initiative Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
The geography of pet parasites is changing The geography of pet parasites is changing Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats
The Unwearable Collection™ Evolution The Unwearable Collection™ Evolution Get ready for the next stage of The Unwearable Collection™
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
Patient Organizations Patient Organizations Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.